Dominari Holdings Past Earnings Performance
Past criteria checks 0/6
Dominari Holdings's earnings have been declining at an average annual rate of -40.2%, while the Biotechs industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 98.5% per year.
Key information
-40.2%
Earnings growth rate
3.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 98.5% |
| Return on equity | -51.5% |
| Net Margin | -721.1% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Dominari Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 3 | -25 | 24 | 0 |
| 31 Dec 23 | 2 | -23 | 24 | 0 |
| 30 Sep 23 | 1 | -23 | 20 | 0 |
| 30 Jun 23 | 0 | -26 | 20 | 1 |
| 31 Mar 23 | 0 | -23 | 13 | 1 |
| 31 Dec 22 | 0 | -26 | 12 | 3 |
| 30 Sep 22 | 0 | -21 | 11 | 3 |
| 30 Jun 22 | 0 | -15 | 8 | 2 |
| 31 Mar 22 | 0 | -10 | 8 | 3 |
| 31 Dec 21 | 0 | -7 | 8 | 2 |
| 30 Sep 21 | 0 | -5 | 6 | 2 |
| 30 Jun 21 | 0 | -7 | 5 | 2 |
| 31 Mar 21 | 0 | -8 | 4 | 2 |
| 31 Dec 20 | 0 | -12 | 4 | 2 |
| 30 Sep 20 | 0 | -12 | 4 | 5 |
| 30 Jun 20 | 0 | -13 | 4 | 4 |
| 31 Mar 20 | 0 | -11 | 4 | 4 |
| 31 Dec 19 | 0 | -4 | 3 | 3 |
| 30 Sep 19 | 0 | 0 | 3 | 0 |
| 30 Jun 19 | 0 | 2 | 3 | 0 |
| 31 Mar 19 | 0 | 2 | 3 | 0 |
| 31 Dec 18 | 0 | 2 | 3 | 0 |
| 30 Sep 18 | 0 | -5 | 4 | 0 |
| 30 Jun 18 | 1 | -2 | 4 | 0 |
| 31 Mar 18 | 1 | -4 | 4 | 0 |
| 31 Dec 17 | 1 | -3 | 4 | 0 |
| 30 Sep 17 | 1 | -6 | 4 | 0 |
| 30 Jun 17 | 1 | -7 | 4 | 0 |
| 31 Mar 17 | 1 | 25 | 4 | 0 |
| 31 Dec 16 | 1 | 25 | 5 | 0 |
| 30 Sep 16 | 1 | 34 | 5 | 0 |
| 30 Jun 16 | 0 | 31 | 5 | 0 |
| 31 Mar 16 | 0 | -39 | 5 | 0 |
| 31 Dec 15 | 0 | -42 | 5 | 0 |
| 30 Sep 15 | 0 | -53 | 7 | 0 |
| 30 Jun 15 | 0 | -55 | 8 | 0 |
| 31 Mar 15 | 0 | -27 | 17 | 0 |
| 31 Dec 14 | 0 | -31 | 21 | 0 |
| 30 Sep 14 | 0 | -29 | 21 | 0 |
| 30 Jun 14 | 0 | -33 | 28 | 0 |
| 31 Mar 14 | 0 | -22 | 20 | 0 |
| 31 Dec 13 | 0 | -18 | 15 | 0 |
| 30 Sep 13 | 0 | -15 | 13 | -1 |
| 30 Jun 13 | 0 | -6 | 4 | -1 |
Quality Earnings: BP2A is currently unprofitable.
Growing Profit Margin: BP2A is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BP2A is unprofitable, and losses have increased over the past 5 years at a rate of 40.2% per year.
Accelerating Growth: Unable to compare BP2A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BP2A is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: BP2A has a negative Return on Equity (-51.52%), as it is currently unprofitable.